Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
- PMID: 36146594
- PMCID: PMC9503770
- DOI: 10.3390/vaccines10091516
Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
Abstract
Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development. MVA is well studied and has been widely used for vaccination against smallpox in Germany. This review describes the history of the origin of the virus and its properties as a vaccine, including a high safety profile. In recent years, MVA has found its place as a vector for the creation of vaccines against various diseases. To date, a large number of vaccine candidates based on the MVA vector have already been developed, many of which have been tested in preclinical and clinical studies. We discuss data on the immunogenicity and efficacy of some of these vaccines.
Keywords: clinical trial; poxvirus; smallpox vaccine; vaccine development; viral vector vaccines.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.Adv Virus Res. 2017;97:187-243. doi: 10.1016/bs.aivir.2016.07.001. Epub 2016 Aug 1. Adv Virus Res. 2017. PMID: 28057259 Free PMC article. Review.
-
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.Biomedicines. 2021 Nov 26;9(12):1780. doi: 10.3390/biomedicines9121780. Biomedicines. 2021. PMID: 34944596 Free PMC article. Review.
-
Generation and Production of Modified Vaccinia Virus Ankara (MVA) as a Vaccine Vector.Methods Mol Biol. 2017;1581:97-119. doi: 10.1007/978-1-4939-6869-5_6. Methods Mol Biol. 2017. PMID: 28374245
-
Clinical development of Modified Vaccinia virus Ankara vaccines.Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Vaccine. 2013. PMID: 23523410 Review.
-
Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus.Biomedicines. 2021 Aug 31;9(9):1122. doi: 10.3390/biomedicines9091122. Biomedicines. 2021. PMID: 34572308 Free PMC article. Review.
Cited by
-
Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity.Vaccines (Basel). 2023 Apr 12;11(4):831. doi: 10.3390/vaccines11040831. Vaccines (Basel). 2023. PMID: 37112743 Free PMC article.
-
Revolutionizing Veterinary Health with Viral Vector-Based Vaccines.Indian J Microbiol. 2024 Sep;64(3):867-878. doi: 10.1007/s12088-024-01341-3. Epub 2024 Jun 21. Indian J Microbiol. 2024. PMID: 39282171 Review.
-
Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.Front Immunol. 2024 Apr 3;15:1277447. doi: 10.3389/fimmu.2024.1277447. eCollection 2024. Front Immunol. 2024. PMID: 38633245 Free PMC article.
-
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.Front Immunol. 2024 Nov 7;15:1478703. doi: 10.3389/fimmu.2024.1478703. eCollection 2024. Front Immunol. 2024. PMID: 39575236 Free PMC article. Review.
-
Research advances in replication-deficient viral vector vaccines.Front Vet Sci. 2025 Mar 3;12:1535328. doi: 10.3389/fvets.2025.1535328. eCollection 2025. Front Vet Sci. 2025. PMID: 40098886 Free PMC article. Review.
References
-
- Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and Its Erradication. World Health Organization; Geneva, Switzerland: 1988. pp. 1–1460.
-
- Orenstein W., Offit P., Edwards K.M., Plotkin S. Plotkin’s Vaccines. 7th ed. Elsevier; Amsterdam, The Netherlands: 2017.
Publication types
LinkOut - more resources
Full Text Sources